These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 8570306

  • 1. Effects of combined treatment with rhDNase and airflow oscillations on spinnability of cystic fibrosis sputum in vitro.
    Dasgupta B, Tomkiewicz RP, Boyd WA, Brown NE, King M.
    Pediatr Pulmonol; 1995 Aug; 20(2):78-82. PubMed ID: 8570306
    [Abstract] [Full Text] [Related]

  • 2. Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I.
    King M, Dasgupta B, Tomkiewicz RP, Brown NE.
    Am J Respir Crit Care Med; 1997 Jul; 156(1):173-7. PubMed ID: 9230743
    [Abstract] [Full Text] [Related]

  • 3. Reduction in viscoelasticity in cystic fibrosis sputum in vitro using combined treatment with nacystelyn and rhDNase.
    Dasgupta B, King M.
    Pediatr Pulmonol; 1996 Sep; 22(3):161-6. PubMed ID: 8893254
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis.
    Shah PL, Scott SF, Knight RA, Marriott C, Ranasinha C, Hodson ME.
    Thorax; 1996 Feb; 51(2):119-25. PubMed ID: 8711640
    [Abstract] [Full Text] [Related]

  • 7. Improved clearability of cystic fibrosis sputum with dextran treatment in vitro.
    Feng W, Garrett H, Speert DP, King M.
    Am J Respir Crit Care Med; 1998 Mar; 157(3 Pt 1):710-4. PubMed ID: 9517580
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effect of recombinant human DNase on alpha1-proteinase inhibitor function: an experimental approach to the combined clinical use of rhDNase and alpha1-PI in CF patients.
    Hansen G, Hoffjan S, Mosler K, Schuster A.
    Lung; 2001 Mar; 179(3):185-94. PubMed ID: 11891608
    [Abstract] [Full Text] [Related]

  • 11. Airway inflammation after treatment with aerosolized deoxyribonuclease in cystic fibrosis.
    Henry RL, Gibson PG, Carty K, Cai Y, Francis JL.
    Pediatr Pulmonol; 1998 Aug; 26(2):97-100. PubMed ID: 9727759
    [Abstract] [Full Text] [Related]

  • 12. Improved activity of an actin-resistant DNase I variant on the cystic fibrosis airway secretions.
    Zahm JM, Debordeaux C, Maurer C, Hubert D, Dusser D, Bonnet N, Lazarus RA, Puchelle E.
    Am J Respir Crit Care Med; 2001 Apr; 163(5):1153-7. PubMed ID: 11316652
    [Abstract] [Full Text] [Related]

  • 13. Recombinant human DNase (rhDNase) influences phospholipid composition, surface activity, rheology and consecutively clearance indices of cystic fibrosis sputum.
    Griese M, App EM, Duroux A, Burkert A, Schams A.
    Pulm Pharmacol Ther; 1997 Apr; 10(1):21-7. PubMed ID: 9344829
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Impact of PEGylation on the mucolytic activity of recombinant human deoxyribonuclease I in cystic fibrosis sputum.
    Guichard MJ, Kinoo D, Aubriot AS, Bauwens N, Gougué J, Vermeulen F, Lebecque P, Leal T, Vanbever R.
    Clin Sci (Lond); 2018 Jul 18; 132(13):1439-1452. PubMed ID: 29871879
    [Abstract] [Full Text] [Related]

  • 17. Aerosolized dornase alfa (rhDNase) for therapy of cystic fibrosis.
    Hodson ME.
    Am J Respir Crit Care Med; 1995 Mar 18; 151(3 Pt 2):S70-4. PubMed ID: 7881698
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.